Impact Factor 2020: 1.226 (@Clarivate Analytics)
5-Year Impact Factor: 2.285 (@Clarivate Analytics)
Immediacy Index: 2.645
  • Users Online: 3231
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2022  |  Volume : 15  |  Issue : 4  |  Page : 171-178

SARS-CoV-2 infection rates after different vaccination schemes: An online survey in Turkey


1 Chest Diseases Department, Faculty of Medicine, Cukurova University, Adana, Turkey
2 Department of Pulmonary Medicine, Delta Hospital, Istanbul, Turkey
3 Chest Diseases Department, Aksaray Training and Research Hospital, Aksaray, Turkey
4 Department of Pulmonary Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey
5 Department of Biostatistics, Hacettepe University, Ankara, Turkey
6 Department of Nuclear Medicine, Integra Medical Imaging Center, Ankara, Turkey

Correspondence Address:
Nurdan Kokturk
Department of Pulmonary Medicine, Faculty of Medicine, Gazi University, Ankara
Turkey
Login to access the Email id

Source of Support: The authors received no extramural funding for the study, Conflict of Interest: None


DOI: 10.4103/1995-7645.340576

Rights and Permissions

Objective: To identify effects of various nationwide vaccination protocols on the evolution of new SARS-CoV-2 infections among adult population and to evaluate the safety of mRNA (BioNTech/ Pfizer) vaccine. Methods: Totally 10 735 adult volunteers that received at least one dose of BioNTech/Pfizer or triple doses of CoronaVac participated in this cross-sectional-online survey between 1 and 10 September 2021. The information was collected covering a 5-month period from April 2021 to September 2021. Information about people who were vaccinated with only single and double dose CoronaVac were not included in this study. Results: At least one side effect after single and double dose of BioNTech/Pfizer and triple doses of CoronaVac were observed in 42.1%, 42.5% and 10.9%, respectively. The most common side effects were shoulder/arm pain, weakness/fatigue, muscle/joint pain and headache. The side effects were the most frequent in single BioNTech/Pfizer, while it was the least in triple CoronaVac. The rate of positive PCR tests before vaccination was 17.6%, and decreased to 3.0% after vaccination. The rates of positive SARS CoV-2-PCR were 18.8%, 3.5%, 3.1%, 0.5% and 4.6% in single BioNTech/Pfizer, double BioNTech/Pfizer, double CoronaVac+single BioNTech/Pfizer, double CoronaVac+double BioNTech/Pfizer and triple CoronaVac, respectively. While 1.8% of PCR positive COVID-19 cases needed intensive unit care in the pre-vaccination period, intensive care unit was required in 0%, 1.5%, 2.4%, 0% and 4.2% after single BioNTech/ Pfizer, double BioNTech/Pfizer, double CoronaVac+single BioNTech/ Pfizer, double CoronaVac+double BioNTech/Pfizer and triple CoronaVac, respectively. Reinfection rate after vaccination was 0.4%. Conclusions: The rarity of COVID-19 infection after vaccination suggests that efficacy of vaccines is maintained. On the other hand, the data underscore the critical importance of continued public health mitigation.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed192    
    Printed8    
    Emailed0    
    PDF Downloaded57    
    Comments [Add]    

Recommend this journal